Form 4: Oric Pharma Director Granted 40,000 Stock Options

Oric Pharmaceuticals director Richard A. Heyman was granted 40,000 stock options with an exercise price of $8.17, vesting monthly over one year.

Summary

• Richard A. Heyman, a Director of Oric Pharmaceuticals, Inc. (ORIC), was granted 40,000 stock options.
• The options have an exercise price of $8.17 per share.
• The grant date for these options was January 2, 2026.
• The options will vest over a 12-month period, with 1/12th of the shares vesting on each one-month anniversary of January 2, 2026.
• The options expire on January 1, 2036.
• This transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options to a director is a standard compensation practice that aligns interests, but the filing itself doesn't provide operational or financial performance news.

Positives

• The grant of stock options to a director aligns management incentives with shareholder interests.
• The transaction was made under a Rule 10b5-1 plan, indicating a pre-planned transaction and potentially reducing concerns about opportunistic trading.

Risks

• The value of the stock options is dependent on the future performance of Oric Pharmaceuticals' stock price. If the stock price does not exceed the exercise price of $8.17, the options may expire worthless.
• Potential for dilution for existing shareholders if options are exercised and new shares are issued.

Future Outlook

This filing is a Form 4, which reports past insider transactions and does not typically contain forward-looking statements or guidance about the company's future operational or financial performance, beyond the future vesting schedule of the options.

Industry Context

This is a routine insider transaction filing, reflecting standard practice for compensating directors with equity to align their interests with long-term shareholder value. Such grants are common across various industries, particularly in biotechnology and pharmaceuticals, to incentivize leadership.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industry, similar to companies like Amgen or Gilead Sciences, to incentivize long-term performance.
• The vesting schedule of 12 months is relatively short for director options, which sometimes vest over 3-4 years, but monthly vesting is also common for shorter-term incentive components.
• The exercise price being fixed at the grant date's market price (implied by the Form 4 structure) is standard for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director is a related party transaction, representing a standard form of compensation disclosed through this filing.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased value if director incentives lead to improved company performance.

Next Steps

• Richard A. Heyman will continue to hold the granted stock options, which will vest monthly over the next 12 months starting January 2, 2026.
• Future Form 4 filings would be required for any subsequent transactions involving these or other Oric Pharmaceuticals securities by Mr. Heyman.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of their compensation, which is a standard practice to align interests. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to alter an existing investment thesis.

Keywords

Oric Pharmaceuticals, ORIC, Stock Options, Insider Trading, Form 4, Director Compensation, Equity Grant, Richard A. Heyman, Rule 10b5-1